ANTI-CD154 ANTIBODY WITH IMPROVED BINDING, FUNCTIONAL AND SAFETY PROPERTIES AND USE IN IMMUNOTHERAPY IN HUMANS

DK3331548T3Active Publication Date: 2026-06-29IMMUNEXT INC LEBANON
0 Cites 0 Cited by

Patent Information

Application Number
DK2016825103T
Authority / Receiving Office
DK · DK
Patent Type
Patents
Current Assignee / Owner
Priority Date
2016-07-13
Filing Date
2016-07-13
Publication Date
2026-06-29
Estimated Expiration
2036-07-13

AI Technical Summary

Technical Problem

Current anti-CD154 antibodies face challenges in achieving a balance between efficacy and safety, with earlier versions experiencing toxicity issues such as thrombogenic events, leading to reduced potency and pharmacokinetic properties.

Method used

Development of a humanized anti-CD154 antibody, INX021, with specific mutations in the Fc region (E269R and K322A) that reduce FcR and C1q binding, enhancing binding affinity and immunosuppressive properties while avoiding pro-thrombotic activities, and incorporating affinity maturation of variable regions to improve binding to CD154.

Benefits of technology

INX021 exhibits a 5-fold greater binding affinity for CD154, improved immunosuppressive activities, and a safer profile by minimizing thrombotic risks, making it more potent and efficacious for human therapy with potential for less frequent dosing in chronic autoimmune and inflammatory indications.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

Improved anti-CD154 antibodies are provided herein which have improved therapeutic potency, in vivo half-life and ablated FcR binding and / or complement binding / activation. The use of these antibodies for inducing tolerance and treating immune diseases including autoimmunity, inflammation, transplant recipients, fibrosis and allergic disorders is disclosed herein.
Need to check novelty before this filing date? Find Prior Art